Company

Xintela AB

Xintela AB is a Lund, Sweden biopharmaceutical company developing stem cell and targeted cancer therapies.

About

Founded in 2009 and headquartered in Lund, Sweden, Xintela AB develops stem cell and targeted cancer therapies for oncology and regenerative medicine. It received SEK 6 million from investors including ALMI Invest and Baulos Capital Belgium in October 2013, its first known round. Evy Lundgren-Åkerlund is CEO. Reported 2022 revenue was SEK 0, with an EBITDA of SEK -6,430,565.1.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in